Relmada Therapeutics Inc (RLMD)

May 22, 2026

RLMD Stock Chart | RELMADA THERAPEUTICS INC (NASDAQ:RLMD) - ChartMill

May 22, 2026

May 19, 2026

Earnings call transcript: Relmada Therapeutics Q1 2026 sees stock dip despite strong cash position By Investing.com - Investing.com South Africa

May 19, 2026

May 19, 2026

Earnings call transcript: Relmada Therapeutics Q1 2026 sees stock dip despite strong cash position - Investing.com

May 19, 2026

May 17, 2026

Relmada Therapeutics, Inc.Common Stock (NQ: RLMD - FinancialContent

May 17, 2026

May 15, 2026

Relmada targets mid-2026 phase 3 RESCUE start backed by $234M cash runway through 2029 - MSN

May 15, 2026

May 15, 2026

Wall Street analysts predict a 92.19% upside in Relmada Therapeutics (RLMD): Here's what you should know - MSN

May 15, 2026

May 13, 2026

Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail

May 13, 2026

May 13, 2026

Relmada Therapeutics Charts Ambitious NDV-01 Phase 3 Path - TipRanks

May 13, 2026

May 13, 2026

Relmada Therapeutics Inc files for mixed shelf offering, size not disclosedSEC filing - marketscreener.com

May 13, 2026

May 13, 2026

Relmada Therapeutics Q1 earnings call highlights - MSN

May 13, 2026

May 13, 2026

Relmada Therapeutics (NASDAQ: RLMD) registers 29.5M shares tied to $160M deal - Stock Titan

May 13, 2026

May 13, 2026

Relmada Therapeutics Q1 Loss per Share Narrows - Moomoo

May 13, 2026

May 13, 2026

Adage Capital reports 4.54% stake in Relmada Therapeutics (NASDAQ: RLMD) - Stock Titan

May 13, 2026

May 13, 2026

Q1 2026 Relmada Therapeutics Inc Earnings Call Transcript - GuruFocus

May 13, 2026

May 13, 2026

Piper Sandler Maintains Relmada Therapeutics(RLMD.US) With Buy Rating, Maintains Target Price $12 - Moomoo

May 13, 2026

May 13, 2026

Relmada Therapeutics, Inc. (NASDAQ:RLMD) Q1 2026 Earnings Call Transcript - Insider Monkey

May 13, 2026

May 13, 2026

Relmada Therapeutics Reports Strong Q1 2026 Results, Highlights Positive NDV-01 Phase 2 Data in Bladder Cancer and Plans for Phase 3 RESCUE Program - Minichart

May 13, 2026

May 13, 2026

Relmada Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update - The Manila Times

May 13, 2026

May 13, 2026

Relmada Therapeutics Inc (RLMD) Q1 2026 Earnings Call Highlights - GuruFocus

May 13, 2026

May 13, 2026

Is Relmada Therapeutics (RLMD) Fairly Valued After Q1 2026? EPS: - GuruFocus

May 13, 2026

May 13, 2026

Relmada Therapeutics Q1 Earnings Call Highlights - sharewise.com

May 13, 2026

May 12, 2026

Transcript : Relmada Therapeutics, Inc., Q1 2026 Earnings Call, May 12, 2026 - marketscreener.com

May 12, 2026

May 12, 2026

Relmada Highlights NDV-01 Phase 2 Data, Phase 3 Plans - TipRanks

May 12, 2026

May 12, 2026

Earnings call transcript: Relmada Therapeutics Q1 2026 results reveal mixed performance - Investing.com Nigeria

May 12, 2026

May 12, 2026

RLMD: NDV-01 shows best-in-class efficacy in NMIBC; cash and patent position support long-term growth - TradingView

May 12, 2026

May 12, 2026

RLMD: NDV-01 demonstrates high efficacy in NMIBC, with robust financials supporting late-stage trials - TradingView

May 12, 2026

May 12, 2026

Transcript: Relmada Therapeutics Q1 2026 Earnings Conference Call - Benzinga

May 12, 2026

May 12, 2026

Relmada (NASDAQ: RLMD) boosts cash with $160M PIPE and NDV-01 data - Stock Titan

May 12, 2026

May 12, 2026

RLMD: NDV-01 demonstrates high response rates in NMIBC, with pivotal trials and strong financial backing ahead - TradingView

May 12, 2026

May 12, 2026

RELMADA THERAPEUTICS ($RLMD) Releases Q1 2026 Earnings - Quiver Quantitative

May 12, 2026

May 12, 2026

RLMD: Robust NDV-01 Phase 2 results and $160M financing support Phase 3 launch and long-term funding - TradingView

May 12, 2026

May 12, 2026

Relmada Therapeutics Q1 net loss widens, cash rises - TradingView

May 12, 2026

May 12, 2026

Earnings Flash (RLMD) Relmada Therapeutics Posts Q1 Loss $0.22, vs. FactSet Est of $0.20 Loss - marketscreener.com

May 12, 2026

May 12, 2026

Relmada Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com

May 12, 2026

May 12, 2026

Relmada Therapeutics (NASDAQ: RLMD) posts Q1 loss, builds cash for NDV-01, sepranolone - Stock Titan

May 12, 2026

May 12, 2026

Relmada Therapeutics Q1 2026 Earnings Call Transcript - MarketBeat

May 12, 2026

May 11, 2026

TradingKey - TradingKey

May 11, 2026

May 10, 2026

Relmada Therapeutics to Report First Quarter 2026 Financial Results on Tuesday, May 12, 2026 - Investing News Network

May 10, 2026

May 09, 2026

Relmada Therapeutics, Inc. (NASDAQ:RLMD) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat

May 09, 2026

May 08, 2026

Relmada Therapeutics Inc expected to post a loss of 19 cents a shareEarnings Preview - TradingView

May 08, 2026

May 08, 2026

Number of shareholders of Relmada Therapeutics Inc – MUN:4E2 - TradingView

May 08, 2026

May 06, 2026

Q2 2025 Relmada Therapeutics Inc Earnings Call Transcript - GuruFocus

May 06, 2026

May 06, 2026

Q3 2025 Relmada Therapeutics Inc Earnings Call Transcript - GuruFocus

May 06, 2026

May 06, 2026

Relmada Therapeutics to Announce First Quarter 2026 Financial Results on May 12 - geneonline.com

May 06, 2026

May 06, 2026

Biotech Relmada will discuss Q1 results and business update May 12 - Stock Titan

May 06, 2026

May 05, 2026

Relmada Therapeutics to Present NDV-01 Abstracts at AUA2026 - Investing News Network

May 05, 2026

May 05, 2026

Bladder cancer drug NDV-01 heads to AUA with Phase 3 on track - Stock Titan

May 05, 2026